Future prospects for use of fibrinolysis inhibitors.
D000176:Acrosin / Q000037:antagonists & inhibitors; D000799:Angioedema / Q000188:drug therapy; D000818:Animals; D000933:Antifibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003167:Complement Activation / Q000187:drug effects; D003272:Contraceptive Agents, Male; D005337:Fibrin; D006801:Humans; D066298:In Vitro Techniques; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D008297:Male; D009504:Neutrophils / Q000201:enzymology; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats
D000933:Antifibrinolytic Agents; D003272:Contraceptive Agents, Male; D011480:Protease Inhibitors; D005337:Fibrin; D000176:Acrosin